Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Clinical Validity of NETest2.0® in Surveillance of Neuroendocrine Tumor Patients: Evidence from a NET Registry Study (NCT02270567).
Journal: Cancers
Published: April 07, 2026
PROSTest, a Novel Liquid Biopsy Molecular Assay, Accurately Guides Prostate Cancer Biopsy Decision-Making in Men with Elevated PSA Irrespective of DRE Findings.
Journal: Cancers
Published: October 24, 2025
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Journal: Lancet (London, England)
Published: April 27, 2020
Time for a change and to adopt a novel molecular genomic approach in NETs.
Journal: Nature reviews. Clinical oncology
Published: February 28, 2019
Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
Journal: The oncologist
Published: November 28, 2017
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Journal: Neurosurgery
Published: November 15, 2013
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Journal: Cancer chemotherapy and pharmacology
Published: November 06, 2012
Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature.
Journal: Oncology
Published: August 22, 2012
Is there a role for liver transplantation in metastatic pancreatic neuroendocrine tumors (PNET)?
Journal: JOP : Journal of the pancreas
Published: May 11, 2012
Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST).
Journal: Anticancer research
Published: April 12, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026